News of Note—Novavax, Walter Reed and more


Here is some other vaccine news of note for the week:

> Novavax has enrolled the first participants in a phase 2 study of its NanoFlu in older adults. Release

> The Walter Reed Army Institute of Research signed a deal with Enesi Pharma for the development of a needle-free Shigella vaccine. Release

> The Biomedical Advanced Research and Development Authority awarded Altimmune an additional $2.5 million to support work on its anthrax vaccine candidate NasoShield. Release

> LineaRx, a subsidiary of Applied DNA, signed on with Takis and Evvivax to developed DNA-based cancer vaccines. Release


Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.